GlassScriptPrepare for your visit
Vanessa Moore
San Francisco, CA · NPI 1093400970
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$292.93
in general payments reported to CMS, 2019-2025 · $248 in 2025
The $248 reported for 2025 was more than what a typical provider received nationally.
Who reported paying
General payments only, top 5 by amount.
- Merck Sharp & Dohme LLC $91.86
- Pfizer INC. $76.41
- Ceribell, INC. $62.96
- Novartis Pharmaceuticals Corporation $34.68
- Viiv Healthcare Company $27.02
Drugs and devices associated with these payments
Zerbaxa Vyndaqel Pocket Eeg Device Rhapsido Cosentyx Rukobia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Vanessa Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11685169/vanessa-moore